Citadel Advisors
SLDB icon

Citadel Advisors’s Solid Biosciences SLDB Stock Holding History

Citadel Advisors’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,600
Closed -$134K – 14750
2026
Q1 		$134K Buy
+18,600
New +$120K ﹤0.01% 11783
2025
Q4 		– Sell
-23,300
Closed -$144K – 13953
2025
Q3 		$144K Sell
23,300
-3,200
-12% -$18.7K ﹤0.01% 11561
2025
Q2 		$129K Sell
26,500
-18,800
-42% -$66.5K ﹤0.01% 11101
2025
Q1 		$168K Buy
45,300
+35,700
+372% +$153K ﹤0.01% 10700
2024
Q4 		$38.4K Buy
9,600
+3,200
+50% +$17.6K ﹤0.01% 12649
2024
Q3 		$44.6K Buy
6,400
+5,300
+482% +$43K ﹤0.01% 12039
2024
Q2 		$6.24K Sell
1,100
-10,600
-91% -$94.9K ﹤0.01% 13348
2024
Q1 		$156K Buy
+11,700
New +$109K ﹤0.01% 10713
2023
Q2 		– Sell
-390
Closed -$1.85K – 15143
2023
Q1 		$1.85K Buy
+390
New +$2.34K ﹤0.01% 14240
2022
Q1 		– Sell
-767
Closed -$20K – 14486
2021
Q4 		$20K Sell
767
-3,140
-80% -$96K ﹤0.01% 13586
2021
Q3 		$140K Buy
3,907
+934
+31% +$39.7K ﹤0.01% 12459
2021
Q2 		$163K Sell
2,973
-4,040
-58% -$267K ﹤0.01% 12407
2021
Q1 		$582K Buy
7,013
+5,546
+378% +$614K ﹤0.01% 9352
2020
Q4 		$167K Buy
+1,467
New +$92.8K ﹤0.01% 9874
2020
Q2 		– Sell
-1,640
Closed -$59K – 10441
2020
Q1 		$59K Sell
1,640
-1,020
-38% -$50.5K ﹤0.01% 8953
2019
Q4 		$178K Buy
2,660
+1,087
+69% +$120K ﹤0.01% 8262
2019
Q3 		$244K Buy
1,573
+826
+111% +$93.5K ﹤0.01% 7873
2019
Q2 		$64K Sell
747
-220
-23% -$24K ﹤0.01% 8661
2019
Q1 		$133K Buy
+967
New +$242K ﹤0.01% 8439

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's SLDB Position: Q2 2026 in Review

Citadel Advisors increased its Solid Biosciences (SLDB) stake by 8.4% in Q2 2026, buying an estimated $1.66M and bringing the position to 2,815,122 shares worth $28.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Citadel Advisors first reported a position in SLDB in Q1 2018 and has held it in 26 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Citadel Advisors held 2,815,122 shares of Solid Biosciences worth $28.1M as of Q2 2026.
  • Citadel Advisors bought 218,322 Solid Biosciences shares in Q2 2026, an estimated $1.66M.
  • Solid Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2175 holding.
  • Citadel Advisors first reported a position in Solid Biosciences in Q1 2018 and has held it in 26 quarters since.
  • 156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.